Drug Approval | August 23, 2024
Wanbury receives EIR from FDA for Patalganga facility
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
The inspection was concluded with two 483 observations
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Renews GMP certifications for India and Malaysia sites
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
The company is committed to address this observation comprehensively within stipulated time
Subscribe To Our Newsletter & Stay Updated
